NCT06065813招募中2 期
The Efficacy and Safety of Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIB-IIIA Non-small Cell Lung Cancer
Northern Jiangsu People's Hospital1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2022年8月8日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Event-free survival
研究概览
简要总结
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients must volunteer participating in clinical trial; patients fully understand and sign the Informed Consent Form (ICF)
- •18 ~ 70 years old, gender not limited
- •Histologically confirmed resectable stage IIA-IIIA NSCLC without prior treatment
- •Patients must have at least one "target" lesion" to be used to assess response on this protocol as defined by RECIST 1.1
- •Agree to provide PD-L1 immune tissue sections and corresponding pathology reports for biomarker evaluation (Tumor tissue samples must be fresh or archived samples obtained within 3 months before enrollment
- •Have a performance status of 0 or 1 on the ECOG Performance Scale
- •Good organ function: ANC ≥ 1500/μL; PLT ≥ 100000/μL; HB ≥ 10.0g/dL; CR ≤ 1.5 × ULN or CrCl ≥ 60 mL/min (Use Cock-Gault formula); TB ≤ 1.5 × ULN (For patients with total bilirubin levels > 1.5 × ULN, direct bilirubin is within normal limits); AST and ALT ≤ 2.5 × ULN; TSH is within normal limits. Note: If TSH is not within the normal range at baseline, if T3 and free T4 are within the normal range, then the patient can still meet the inclusion criteria. IN、RPT、APTT≤1.5×ULN
- •Patients must volunteer and be able to follow research plan visits, treatment plans, laboratory tests, and other research procedures
- •According to the surgeon's assessment, the total lung function can withstand the proposed lung resection
- •Within 3 days before medication，the serum of fertile woman must be tested by hcg，and the result is negative. Fertile women can use high effective method for contraception in the duration of clinical trail and 180 days after last Administration
排除标准
- •Locally advanced unresectable or metastatic disease
- •Non-small small lung cancer (NSCLC) involving the upper sulcus，large cell neuroendocrine cancer (LCNEC), sarcomatoid tumor
- •Patients with known EGFR mutations or ALK translocations, non-squamous carcinoma patients need to know the status of EGFR and ALK mutations
- •Early NSCLC with prior systemic anticancer therapy, including experimental drug therapy
- •Have a history of (non-infectious) pneumonia / interstitial lung disease requiring steroid therapy, or currently have pneumonia / interstitial lung disease requiring steroid therapy
- •Known history of active tuberculosis
- •Known to have active infection requiring systemic treatment
- •known or suspected autoimmune diseases or immunodeficiency, except: patients with a history of hypothyroidism who do not require hormone therapy or are receiving physiological dose hormone replacement therapy; patients with stable type 1 diabetes whose blood glucose is controlled
- •Active hepatitis B or C
- •Has a known history of Human Immunodeficiency Virus (HIV) .
- •Received live vaccine treatment within 30 days before drug administration; but inactivated viral vaccine for seasonal influenza is allowed
- •Peripheral neuropathy ≥ grade 2
- •Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- •Overly sensitive reaction to other monoclonal antibodies
- •Have a history of severe allergies to pemetrexed, paclitaxel or docetaxel, cisplatin, carboplatin or their preventive medicine
- •Known to have serious or uncontrolled underlying disease
- •According to the investigator's judgment, the patient has a history or current evidence of any disease, treatment or laboratory abnormality that may confuse the test results, interfere with the participant's participation in the full trial, or not in the best interest of the participant to participate in the trial
研究组 & 干预措施
Toripalimab
Experimental
干预措施: Toripalimab (Drug)
Toripalimab
Experimental
干预措施: Conventional segmental radiotherapy (Radiation)
Toripalimab
Experimental
干预措施: opreation (Other)
结局指标
主要结局
Event-free survival
时间窗: 42months
The time from the beginning of enrollment to the occurrence of any events, including death, disease progression, change of chemotherapy regimen, change of chemotherapy, addition of other treatments, the occurrence of fatal or intolerant side effects and other events
Major pathologic response rates
时间窗: 42months
Major pathological response rates assessed by independent center pathology
次要结局
- Disease-free survival(42 months)
- Overall survival(42 months)
- Pathologic complete response (pCR) rates(42months)
- Number of Participants Experiencing Adverse Events (AEs) and serious adverse events (SAEs)(42 months)
研究者
Buhai Wang
Director
Northern Jiangsu People's Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal CancerImmunotherapyNCT05479240Fujian Cancer Hospital94
尚未招募
3 期
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction ImmunochemotherapyNon-small Cell Lung Cancer Stage IIINCT06031597Zhejiang Cancer Hospital105
已完成
1 期
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung CancerHigh-Risk Resectable NSCLCNCT03732664Second Affiliated Hospital, School of Medicine, Zhejiang University27
撤回
2 期
Neoadjuvant Immunotherapy to ESCCEsophagus SCCNCT04625543Qilu Hospital of Shandong University
已完成
2 期
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)Stage III Non-small Cell Lung CancerNCT01102231Intergroupe Francophone de Cancerologie Thoracique106